TARRYTOWN, N.Y., June 10, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has reported findings from studies of two of its oncology product candidates at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.
Data from studies of MIP-1095, a PSMA targeting small molecule radiotherapeutic, and 99mTc-MIP-1404, a PSMA targeted imaging agent, are featured in oral presentations. Both product candidates are recent additions to Progenics' expanded oncology pipeline following the company's acquisition of Molecular Insight Pharmaceuticals, Inc. Abstracts for these presentations are available on the Events section of Progenics' website:
Robert J. Israel, M.D., senior vice president of medical affairs and clinical research for Progenics, commented, "Ongoing studies of product candidates targeted to PSMA, an enzyme expressed on the neovasculature of almost all prostate cancer cells, potentially could lead to the development of highly specific prostate cancer imaging and treatment options. We are developing candidates that could improve outcomes for cancer patients, including the two candidates featured here at SNMMI in oral presentations as well as our phase 2-stage PSMA antibody-drug conjugate." Additionally, Progenics is presenting details of its oncology pipeline at exhibit booth #142 at the Meeting. About MIP-1095, a PSMA targeting small molecule radiotherapeutic MIP-1095 is in preclinical development for the treatment of metastatic prostate cancer. The compound is radiolabeled with the therapeutic radionuclide, iodine-131, a beta-particle-emitting radionuclide capable of destroying tumor cells. The anticancer effect of 1095 relies on its ability to deliver lethal doses of radiation to prostate cancer cells while causing minimal damage to healthy surrounding tissue.
Oral Presentation #119: Enhancement of prostate-targeted radiotherapy using [131I] MIP-1095 in combination with radiosensitizing chemotherapeutic drugsOral Presentation #281: PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): Phase I studies with 99mTc-MIP-1404
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV